Table 3. EFV-modulated UCRs implicated in tumor progression and localized at cancer associated genomic break sites.
| Name | EFV modulation |
Type | Length | Chr | Break sites | Tumor | References |
|---|---|---|---|---|---|---|---|
| uc.24 | down | n | 336 | 1 | LOH | 32 | |
| uc.28 | down | e | 355 | 1 | FRA | 32 | |
| uc.135 | down | e | 201 | 3 | EVI1 | CLL | 58 |
| uc.144 | down | e | 205 | 4 | CLL/CRC | 58 | |
| uc.193 | down | e | 319 | 6 | LOH | 32 | |
| uc.194 | down | e | 201 | 6 | LOH | 32 | |
| uc.215 | down | n | 262 | 7 | 32 | ||
| uc.276 | down | p | 432 | 9 | LOH | 32 | |
| uc.308 | down | p | 277 | 10 | LOH | 32 | |
| uc.343 | down | e | 388 | 12 | FRA12A/LOH | 33, 32 | |
| uc.345 | down | e | 301 | 12 | FRA12A | 33 | |
| uc.388 | down | n | 298 | 15 | High CRC | CRC | 32 |
| uc.457 | down | e | 211 | 22 | CRC | ||
| uc.20 | up | p | 269 | 1 | HCC | ||
| uc.38 | up | n | 224 | 1 | FRA1F | 33 | |
| uc.158 | up | n | 224 | 5 | CRC | ||
| uc.234 | up | p | 272 | 7 | CRC | ||
| uc.274 | up | p | 327 | 9 | LOH | HCC | 32 |
| uc.292 | up | e | 217 | 10 | MLR2 | CRC | 32 |
| uc.295 | up | n | 209 | 10 | LOH | 32 | |
| uc.303 | up | n | 272 | 10 | LOH | 32 | |
| uc.352 | up | n | 200 | 13 | FRA | CLL | 32 |
| uc.365 | up | n | 278 | 14 | LOH | 32 | |
| uc.398 | up | p | 322 | 16 | CRC |
FRA, fragile site; LOH, loss of heterozygosity; CRC, colorectal ca; CLL, chronic lymphocytic leukemia; HCC, hepatocellular carcinoma.